EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Chimeric Antigen Receptor—Macrophages in Pancreatic Cancer: Promise, Pitfalls, and the Path Ahead

Palloma Porto Almeida, Leandro Martins de Freitas

Frontiers in Bioscience-Elite · 2026-05-28 · 18 (2)

DOI: 10.31083/fbe45762 ↗

At a glance

Übersichtsarbeit in Frontiers in Bioscience-Elite, published online on 2026-05-28. Written by Palloma Porto Almeida and 1 co-authors. Institution: Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil. Major MEDLINE topics: Pancreatic Neoplasms, Receptors, Chimeric Antigen, Macrophages, Carcinoma, Pancreatic Ductal. 29 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Chimeric antigen receptor–engineered macrophages (CAR-Ms) are emerging as a transformative frontier in immunotherapy and represent a promising strategy for pancreatic cancer. Unlike chimeric antigen receptor T-cell (CAR-T) or chimeric antigen receptor natural killer cell (CAR-NK) cells, which encounter limitations when applied to solid tumors, CAR-Ms combine innate tumor-homing capabilities with engineered antigen specificity to overcome these barriers. Recent studies have demonstrated encouraging antitumor activity in preclinical pancreatic ductal adenocarcinoma (PDAC) models; however, key questions remain regarding the persistence, safety, and scalability of these models. Nonetheless, despite these uncertainties, CAR-Ms may represent a paradigm shift from immune activation focused solely on direct cytotoxicity to one that also integrates immune orchestration and tumor microenvironmental reprogramming.

Subjects

MeSH terms (MEDLINE)

Pancreatic NeoplasmsReceptors, Chimeric AntigenMacrophagesCarcinoma, Pancreatic DuctalHumansAnimalsTumor MicroenvironmentImmunotherapy

Author keywords

cellular therapychimeric antigen receptormacrophagestumor microenvironment

Substances

Receptors, Chimeric Antigen

Authors and institutions

  • Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil.
  • Multidisciplinary Institute of Health, Federal University of Bahia, Vitória da Conquista, BA 45029-094, Brazil.

Cite

APA

Almeida, P. P., & de Freitas, L. M. (2026). Chimeric Antigen Receptor—Macrophages in Pancreatic Cancer: Promise, Pitfalls, and the Path Ahead. Frontiers in Bioscience-Elite, 18(2). https://doi.org/10.31083/fbe45762

Vancouver

Almeida PP, de Freitas LM. Chimeric Antigen Receptor—Macrophages in Pancreatic Cancer: Promise, Pitfalls, and the Path Ahead. Frontiers in Bioscience-Elite. 2026;18(2). doi:10.31083/fbe45762

BibTeX
@article{Almeida2026,
  author = {Almeida, Palloma Porto and de Freitas, Leandro Martins},
  title = {Chimeric Antigen Receptor—Macrophages in Pancreatic Cancer: Promise, Pitfalls, and the Path Ahead},
  journal = {Frontiers in Bioscience-Elite},
  year = {2026},
  volume = {18},
  number = {2},
  doi = {10.31083/fbe45762}
}
Start for free →